Olaparib (Lynparza®) is a PARP inhibitor, which means it targets an enzyme (PARP) that can cause cancer growth in those with inherited BRCA mutations. This oral medication is used to treat HER2-negative, previously treated breast cancers that are metastatic or early stage with a high risk of returning.
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Stay in the know with the latest research news, insights, and resources delivered to your inbox.
Follow BCRF on all the major platforms for research news, inspiring stories, and more.
